יוקריאס 50/850 מ"ג

Страна: Ізраїль

мова: іврит

Джерело: Ministry of Health

Активний інгредієнт:

METFORMIN HYDROCHLORIDE 850 MG; VILDAGLIPTIN 50 MG

Доступна з:

NOVARTIS PHARMA SERVICES AG

Код атс:

A10BA02

Фармацевтична форма:

FILM COATED TABLETS

Адміністрація маршрут:

PER OS

Виробник:

NOVARTIS PHARMA STEIN AG, SWITZERLAND

Терапевтична група:

METFORMIN

Терапевтичні свідчення:

Eucreas is indicated in the treatment of type 2 diabetes mellitus:• Eucreas is indicated in the treatment of type 2 diabetes patients who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.• Eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.• Eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

Дата Авторизація:

2010-07-01